Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592590561> ?p ?o ?g. }
- W2592590561 endingPage "51" @default.
- W2592590561 startingPage "43" @default.
- W2592590561 abstract "Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC." @default.
- W2592590561 created "2017-03-16" @default.
- W2592590561 creator A5002383005 @default.
- W2592590561 creator A5011627191 @default.
- W2592590561 creator A5018933113 @default.
- W2592590561 creator A5025051235 @default.
- W2592590561 creator A5025797878 @default.
- W2592590561 creator A5037451302 @default.
- W2592590561 creator A5052879426 @default.
- W2592590561 creator A5057926104 @default.
- W2592590561 creator A5077600317 @default.
- W2592590561 creator A5088022548 @default.
- W2592590561 creator A5091765229 @default.
- W2592590561 date "2017-05-01" @default.
- W2592590561 modified "2023-10-02" @default.
- W2592590561 title "Management of metastatic castration-resistant prostate cancer: A focus on radium-223" @default.
- W2592590561 cites W1193303306 @default.
- W2592590561 cites W1481575351 @default.
- W2592590561 cites W1567908757 @default.
- W2592590561 cites W1802975354 @default.
- W2592590561 cites W1844925317 @default.
- W2592590561 cites W1907774037 @default.
- W2592590561 cites W1940107389 @default.
- W2592590561 cites W1974262630 @default.
- W2592590561 cites W1975577875 @default.
- W2592590561 cites W1992624438 @default.
- W2592590561 cites W1995835470 @default.
- W2592590561 cites W2011238557 @default.
- W2592590561 cites W2011332984 @default.
- W2592590561 cites W2012476754 @default.
- W2592590561 cites W2020593736 @default.
- W2592590561 cites W2021716313 @default.
- W2592590561 cites W2038735381 @default.
- W2592590561 cites W2039413693 @default.
- W2592590561 cites W2065574422 @default.
- W2592590561 cites W2066328231 @default.
- W2592590561 cites W2071633854 @default.
- W2592590561 cites W2077818779 @default.
- W2592590561 cites W2088958029 @default.
- W2592590561 cites W2101285661 @default.
- W2592590561 cites W2103365438 @default.
- W2592590561 cites W2108418975 @default.
- W2592590561 cites W2110534364 @default.
- W2592590561 cites W2110583473 @default.
- W2592590561 cites W2113746964 @default.
- W2592590561 cites W2114608969 @default.
- W2592590561 cites W2120292596 @default.
- W2592590561 cites W2120733363 @default.
- W2592590561 cites W2122904975 @default.
- W2592590561 cites W2123526148 @default.
- W2592590561 cites W2134637689 @default.
- W2592590561 cites W2137458001 @default.
- W2592590561 cites W2137467802 @default.
- W2592590561 cites W2141454098 @default.
- W2592590561 cites W2143841075 @default.
- W2592590561 cites W2144827656 @default.
- W2592590561 cites W2148643283 @default.
- W2592590561 cites W2156923287 @default.
- W2592590561 cites W2158639339 @default.
- W2592590561 cites W2166918329 @default.
- W2592590561 cites W2167331614 @default.
- W2592590561 cites W2168083201 @default.
- W2592590561 cites W2170731023 @default.
- W2592590561 cites W2208460580 @default.
- W2592590561 cites W2235523093 @default.
- W2592590561 cites W2264243378 @default.
- W2592590561 cites W2278392405 @default.
- W2592590561 cites W2283896427 @default.
- W2592590561 cites W2303128566 @default.
- W2592590561 cites W2306024814 @default.
- W2592590561 cites W2320663754 @default.
- W2592590561 cites W2331434899 @default.
- W2592590561 cites W2334143497 @default.
- W2592590561 cites W2470061424 @default.
- W2592590561 cites W2474373162 @default.
- W2592590561 cites W2483834070 @default.
- W2592590561 cites W2484376512 @default.
- W2592590561 cites W2589852745 @default.
- W2592590561 cites W2602037350 @default.
- W2592590561 cites W913623683 @default.
- W2592590561 doi "https://doi.org/10.1016/j.critrevonc.2017.03.001" @default.
- W2592590561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28427521" @default.
- W2592590561 hasPublicationYear "2017" @default.
- W2592590561 type Work @default.
- W2592590561 sameAs 2592590561 @default.
- W2592590561 citedByCount "26" @default.
- W2592590561 countsByYear W25925905612017 @default.
- W2592590561 countsByYear W25925905612018 @default.
- W2592590561 countsByYear W25925905612019 @default.
- W2592590561 countsByYear W25925905612020 @default.
- W2592590561 countsByYear W25925905612021 @default.
- W2592590561 countsByYear W25925905612022 @default.
- W2592590561 countsByYear W25925905612023 @default.
- W2592590561 crossrefType "journal-article" @default.
- W2592590561 hasAuthorship W2592590561A5002383005 @default.
- W2592590561 hasAuthorship W2592590561A5011627191 @default.
- W2592590561 hasAuthorship W2592590561A5018933113 @default.
- W2592590561 hasAuthorship W2592590561A5025051235 @default.